Investment Strategy - The Value Lab focuses on long-only value ideas, targeting international mispriced equities with a portfolio yield of about 4% [1] - The Valkyrie Trading Society shares high-conviction developed market ideas that are downside limited and aim to generate non-correlated and outsized returns [3] Services Offered - The Value Lab provides members with a portfolio featuring real-time updates, 24/7 chat support, global market news reports, feedback on member stock ideas, new trades monthly, quarterly earnings write-ups, and daily macro opinions [2] Performance and Experience - The Value Lab has performed well over the last 5 years, leveraging experience in international markets [1]

SECAUCUS, N.J., Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m. Eastern Time.The fireside chat and Q&A session will be webcast live during the conference and will be ...

CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at htt ...

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference  Presentation Date:December 4, 2024  Time:7:55 ...

Core Insights - Mapi Pharma Ltd. is participating in the 7th Annual Evercore HealthCONx Conference from December 3-5, 2024, in Coral Gables, Florida, to explore partnership opportunities for its innovative long-acting depot injectable treatments [1][2]. Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing Lifecycle Management products using extended-release Depot technologies across various therapeutic areas, including multiple sclerosis (MS), diabetes, and schizophrenia [3][6]. - The company has a strong intellectual property (IP) portfolio and is engaged in the development of high barrier-to-entry and high added-value life cycle management products [6]. Development and Manufacturing Capabilities - Mapi Pharma has a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply, allowing for efficient integration of R&D, clinical studies, registration, and manufacturing [4]. - The company has a dedicated R&D team and Depot labs, which enhance its capabilities in developing Depot products [4]. Partnership Opportunities - Mapi Pharma is actively seeking partnerships for its proprietary Depot products, including Deutetrabenazine (AUSTEDO® XR) Depot for Huntington's disease and Anastrazole (Arimidex®) Depot for hormone receptor-positive early breast cancer [5]. - The company offers to conduct formulation development, preclinical studies, and manage clinical development for partners, who will finance development costs and handle commercialization [5]. Product Pipeline - Mapi's lead product, GA Depot, is partnered with Viatris for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [6]. - The company is also developing Depot drugs for various conditions, including schizophrenia, diabetes, weight control, Parkinson's disease, and potentially Alzheimer's [6].

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS diseases [3] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX®2-73 targets SIGMAR1 and muscarinic receptors, aiming to restore cellular homeostasis and has demonstrated various beneficial properties in preclinical studies [3] Upcoming Events - Christopher U. Missling, PhD, President and CEO of Anavex, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1] - The conference will feature over 600 industry experts and corporate leaders from more than 225 healthcare companies, covering major healthcare verticals [2] Research and Development - Anavex has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of ANAVEX®2-73 for Parkinson's disease [3] - Another drug candidate, ANAVEX®3-71, is in clinical stages and shows promise in addressing Alzheimer's disease hallmarks in preclinical trials [3]

NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media ...

Core Insights - Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies [3] - The company will have its President and CEO, Steven Kelly, participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 5th at 9:35 am ET [1] - An audio webcast of the event will be available on the company's Investor Relations webpage and archived for a limited time [2] Company Overview - Carisma Therapeutics utilizes a proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for cancer and other serious diseases [3] - The company is headquartered in Philadelphia, PA [3] - For more information, the company’s website is www.carismatx.com [3]

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours afte ...

WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows ...